Cambrex Adds R&D Lab for Generic APIs
Pharmaceutical Technology's In the Lab eNewsletter
Cambrex expands its generic API research and development capabilities at its Milan, Italy site.
Cambrex Corporation continued its expansion plans with a June 12, 2018 announcement of the construction of a new 150-sq.-meter R&D laboratory at its site in Paullo, Milan, Italy. The company also announced the recruitment of additional scientists to increase the number of generic APIs in the company’s development portfolio.
The laboratory, which will combine chemistry and analytical development capabilities, will include 14 fume hoods, glass-lined reactors, and liquid chromatography and gas chromatography systems. The company reported in a press statement that construction will be completed by the end of 2018, with installation and validation of instruments to take place in the first quarter of 2019.
The Milan site comprises seven production departments, including a pilot plant, kilo-scale plant, and development and analytical laboratories.
Source: Cambrex
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
